C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Seeking Alpha
Andrew Hirsch - CEO, President & Director Leonard M. J. Reyno - Chief Medical Officer Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Presentation Etzer Darout Barclays Bank PLC, Research Division Good morning, everyone. Welcome to Barclays 28th Annual Global Healthcare Conference. I'm Etzer Darout, Senior Biotech Analyst at Barclays. It's my pleasure to have C4 Therapeutics with us this morning to kick us off. I have Andrew Hirsch, CEO; Len Reyno, Chief Medical Officer from C4 Therapeutics. And Andrew, maybe you can just get us going with just an overview of C4 Therapeutics and then the upcoming milestones that you think are key and are worth noting to investors? Andrew Hirsch CEO, President & Director Yes, absolutely, and thanks for having us. It's great to be here. So for those of you who are not familiar with C4, C4 is a targeted protein degradation company. And we use our degradation platform with the goal of developing medici
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact [Seeking Alpha]Seeking Alpha
- C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
CCCC
Earnings
- 2/26/26 - Beat
CCCC
Sec Filings
- 3/9/26 - Form 144
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- CCCC's page on the SEC website